Results 1 to 10 of about 23,605 (104)

Factors associated with viral rebound among COVID-19 patients receiving oral antivirals [PDF]

Journal of the Formosan Medical Association, 2023
Background: COVID-19 rebound is usually reported among patients experiencing concurrent symptomatic and viral rebound. But longitudinal viral RT-PCR results from early stage to rebound of COVID-19 was less characterized.
Chang Shan-chwen, Jann-Tay Wang, Chi-Tai Fang   +2 more
exaly   +4 more sources

Evaluating the effects of community-based programs on viral rebound and viral suppression among HIV-positive orphaned and vulnerable children receiving antiretroviral treatment: Findings from the ACHIEVE project in Tanzania. [PDF]

PLoS ONE
BackgroundAchieving and sustaining viral load suppression (VLS) among children living with HIV remains challenging despite the availability of antiretroviral therapy (ART), primarily due to adherence difficulties.
Amon Exavery, Daisy Kisyombe, Alison Koler, John Charles, Nemes Mallya, Erica Kuhlik, Asheri Barankena, Rose Fovo, Godfrey Martin Mubyazi, Tom Ventimiglia, Jennifer Mulik, Gloria Sangiwa, Levina Kikoyo   +12 more
doaj   +2 more sources

Incidences and factors associated with viral suppression or rebound among HIV patients on combination antiretroviral therapy from three counties in Kenya

International Journal of Infectious Diseases, 2020
Background: Limited data are available on the incidence and factors associated with viral rebound following viral suppression among HIV-infected individuals taking antiretroviral therapy (ART) in Kenya.
Raphael Lwembe, Asma Adan, Edward Kithela Maina   +2 more
exaly   +3 more sources

Viral rebound and safety of nirmatrelvir/ritonavir for lung-transplant recipients infected with SARS-CoV-2 [PDF]

Biosafety and Health, 2023
Data on the viral rebound and safety of nirmatrelvir/ritonavir in lung transplant (LTx) recipients are limited. The study prospectively followed four LTx recipients.
Hui Li, Li Zhao, Ke Huang, Xiaoxing Wang, Fei Zhou, Yiming Feng, Liang Ma, Bin Cao, Wenhui Chen   +8 more
doaj   +2 more sources

HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys. [PDF]

PLoS Pathogens, 2022
A key challenge for the development of a cure to HIV-1 infection is the persistent viral reservoir established during early infection. Previous studies using Toll-like receptor 7 (TLR7) agonists and broadly neutralizing antibodies (bNAbs) have shown ...
Brian Moldt, Abishek Chandrashekar, Erica N Borducchi, Joseph P Nkolola, Heather Stephenson, Mark Nagel, Magdeleine Hung, Joshua Goldsmith, Craig S Pace, Brian Carr, Nathan D Thomsen, Wade S Blair, Romas Geleziunas, Dan H Barouch   +13 more
doaj   +2 more sources

Impact of antiretroviral therapy in primary HIV infection on natural killer cell function and the association with viral rebound and HIV DNA following treatment interruption [PDF]

Frontiers in Immunology, 2022
Natural Killer (NK) cells play a key role in controlling HIV replication, with potential downstream impact on the size of the HIV reservoir and likelihood of viral rebound after antiretroviral therapy (ART) cessation.
Matthew Pace, Ane Ogbe, Jacob Hurst, Nicola Robinson, Jodi Meyerowitz, Natalia Olejniczak, John P. Thornhill, John P. Thornhill, Mathew Jones, Anele Waters, Julianne Lwanga, Kristen Kuldanek, Rebecca Hall, Panagiota Zacharopoulou, Genevieve E. Martin, Genevieve E. Martin, Helen Brown, Nneka Nwokolo, Dimitra Peppa, Julie Fox, Sarah Fidler, Sarah Fidler, Sarah Fidler, John Frater, John Frater   +24 more
doaj   +2 more sources

Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance.

Journal of Virology
In a subset of SARS-CoV-2-infected individuals treated with the antiviral nirmatrelvir-ritonavir, the virus rebounds following treatment. The mechanisms driving this rebound are not well understood.
Tin Phan, Alan S. Perelson, Ruy M. Ribeiro   +2 more
exaly   +3 more sources

HIV viral suppression and risk of viral rebound in patients on antiretroviral therapy: a two- year retrospective cohort study in Northern Tanzania [PDF]

BMC Infectious Diseases
Background The world is moving towards the third target of the Joint United Nations Programme on HIV/AIDS to ensure most people receiving antiretroviral therapy (ART) are virologically suppressed.
Monica S Kahabuka, Yimtubezinash Woldeamanuel, Peter M. Mbelele, Emmanuel A. Mpolya, Stellah G. Mpagama, Jonas P. Kessy, Tsegahun Manyazewal   +6 more
doaj   +2 more sources

Assessing the impact of autologous virus neutralizing antibodies on viral rebound time in postnatally SHIV-infected ART-treated infant rhesus macaques [PDF]

Epidemics
While the benefits of early antiretroviral therapy (ART) initiation in perinatally infected infants are well documented, early initiation is not always possible in postnatal pediatric HIV infections.
Ellie Mainou, Stella J. Berendam, Veronica Obregon-Perko, Emilie A. Uffman, Caroline T. Phan, George M. Shaw, Katharine J. Bar, Mithra R. Kumar, Emily J. Fray, Janet M. Siliciano, Robert F. Siliciano, Guido Silvestri, Sallie R. Permar, Genevieve G. Fouda, Janice McCarthy, Ann Chahroudi, Jessica M. Conway, Cliburn Chan   +17 more
doaj   +2 more sources

Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies [PDF]

Clinical Infectious Diseases, 2022
Steven G Deeks, Jonathan Z Li, Bernard Macatangay   +2 more
exaly   +2 more sources